Daratumumab

Daratumumab is a monoclonal antibody that targets the CD38 protein, which is a cell surface antigen found in high numbers on multiple myeloma cells. By binding to CD38, daratumumab induces cell death through several mechanisms:

1. Complement-Dependent Cytotoxicity (CDC): Daratumumab activates the complement system, a part of the immune system, leading to the formation of the membrane attack complex that lyses the myeloma cells.

2. Antibody-Dependent Cellular Cytotoxicity (ADCC): The binding of daratumumab to CD38 attracts immune effector cells, like natural killer (NK) cells, which then attack and kill the cancerous cells.

3. Antibody-Dependent Cellular Phagocytosis (ADCP): The binding also promotes recognition and engulfment of myeloma cells by phagocytes, like macrophages.

4. Direct Apoptosis: Daratumumab may directly induce apoptosis, or programmed cell death, in myeloma cells via cross-linking and aggregation of CD38.

These actions help reduce the number of cancer cells in the body, contributing to the management of multiple myeloma and other related conditions.

For more specific inquiries or health guidance, please consult a healthcare professional.

Daratumumab is primarily used in the treatment of multiple myeloma, a type of blood cancer. Clinical studies and trials have provided insights into its efficacy and application:

1. Multiple Myeloma:

   • Daratumumab has shown effectiveness in treating newly diagnosed and relapsed or refractory multiple myeloma. It is often part of combination therapies, enhancing treatment outcomes.
   • A real-world retrospective analysis highlighted its application in relapsed or refractory cases, supporting its use in various clinical settings (Asia-Pacific Journal of Clinical Oncology, 2026).
   • Clinical trials such as NCT03311828 and NCT03224507 have investigated its potential to achieve deep remission and evaluated its role alongside other treatments, like Elranatamab (NCT05020236).

2. Smoldering Multiple Myeloma and MGUS:

   • Daratumumab is being studied for its role in high-risk smoldering multiple myeloma, aiming for early intervention to prevent disease progression (NCT03236428).

3. Kidney Transplant Rejection:

   • An article in the Clinical Kidney Journal (2026) provided evidence that daratumumab may help manage antibody-mediated kidney allograft rejection, offering a potential therapeutic approach beyond oncology.

4. Light-Chain Amyloidosis:

   • Though a study (NCT05486481) was withdrawn, daratumumab is being explored in systemic light-chain amyloidosis, particularly when translocation (11;14) is present, indicating ongoing interest in expanding its clinical applications.

5. Safety Concerns:

   • Studies have noted a high prevalence of iron deficiency in patients receiving daratumumab, necessitating monitoring during treatment (British Journal of Haematology, 2026).
   • Managing infusion-related reactions is crucial, with research into premedication approaches to minimize these effects (Biological & Pharmaceutical Bulletin, 2026).

Overall, daratumumab's roles across multiple conditions and ongoing studies suggest its expanding use beyond its established indications in multiple myeloma. The evidence supports its integration into treatment protocols, reflecting meaningful advancements in managing complex conditions.

Disclaimer: This content is for informational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your healthcare provider with any questions you may have regarding a medical condition.

Daratumumab is a monoclonal antibody used to treat multiple myeloma and other conditions. This overview provides insights into its safety profile based on the available evidence.

Known Side Effects

Daratumumab is associated with several known side effects:

• Infusion-Related Reactions: These are common during treatment. A study mentioned preventive effects of antihistamines to mitigate these reactions. Symptoms can include fever, chills, dyspnea, and nausea.
• Hematological Effects: High prevalence of iron deficiency has been noted among patients, particularly in those with newly diagnosed multiple myeloma.

Contraindications

The evidence does not explicitly list specific contraindications. However, standard practice would suggest caution in patients with known hypersensitivity to daratumumab or any of its components.

Drug Interactions

Information on specific drug interactions with daratumumab is not thoroughly covered in the provided studies. Therefore, interactions with other medications as part of combination therapies should be monitored closely, often necessitating a tailored approach under clinical supervision.

Populations to Avoid

While the evidence regarding specific populations to avoid is thin, caution is generally advised in:

• Pregnant or Nursing Women: Monoclonal antibodies can cross the placenta and may affect fetal development.
• Patients with Severe Respiratory Conditions: Due to the risk of infusion-related reactions that may exacerbate respiratory issues.

This summary is based solely on the available evidence and could benefit from further large-scale studies to clarify and expand upon these findings. As always, treatment decisions should be made in consultation with a healthcare professional.

Disclaimer: This content is for informational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition.

Research on daratumumab focuses on its application in various conditions, primarily multiple myeloma and certain transplant rejections.

1. Kidney Allograft Rejection: A study in the Clinical Kidney Journal examined daratumumab's effects in antibody-mediated kidney allograft rejection. Using serial protocol biopsies, the study highlighted its potential therapeutic role, although detailed methodology such as sample size was not specified.

2. Multiple Myeloma: Several studies focus on daratumumab for newly diagnosed and relapsed multiple myeloma. A paper from the Zhongguo Shi Yan Xue Ye Xue Za Zhi applied a multi-model study and clinical decision analysis to assess early death risk in newly diagnosed patients treated with daratumumab. Additionally, a retrospective analysis in the Asia-Pacific Journal of Clinical Oncology reviewed its use in relapsed or refractory cases in Australia, indicating effectiveness but lacking detailed quantitative data.

3. Iron Deficiency and Treatment Complications: The British Journal of Haematology noted a high prevalence of iron deficiency among newly diagnosed multiple myeloma patients treated with daratumumab, suggesting the need for monitoring and management strategies.

4. Treatment-Related Reactions: A prospective observational study in the Biological & Pharmaceutical Bulletin compared non-sedating and sedating antihistamines as premedications to prevent infusion-related reactions, highlighting options to minimize adverse effects during subcutaneous administration.

5. Smoldering Multiple Myeloma: A phase II trial (NCT03236428) is currently not recruiting but is investigating daratumumab in high-risk MGUS and low-risk smoldering multiple myeloma, reflecting ongoing interest in its early-intervention potential.

Overall, clinical trials and papers show that daratumumab is extensively studied in multiple myeloma, with additional explorations in rejection management and safety improvements.

Disclaimer: This summary is for informational purposes only and not a substitute for professional medical advice.

Daratumumab is a monoclonal antibody used in the treatment of multiple myeloma, among other conditions. The typical dosing and administration protocols for daratumumab may vary depending on the specific condition being treated and the patient's response. Below are some general guidelines:

1. Multiple Myeloma: Daratumumab is often given as an intravenous infusion, and more recently in some cases, as a subcutaneous injection.

   • Initial dosing schedules often involve weekly infusions for a period, such as the first 8 weeks.
   • This may be followed by bi-weekly doses for several cycles.
   • Eventually, it may progress to monthly doses as a maintenance therapy.
   • Patients are typically premedicated with corticosteroids, antipyretics, and antihistamines to reduce infusion-related reactions.

2. Kidney Allograft Rejection: While evidence is limited, daratumumab has shown promise in treating antibody-mediated rejection. The specific dosing regimen for this use is less well-defined in the literature and may vary.

These are standard protocols reported, but individual treatment plans may differ based on patient-specific factors and healthcare provider recommendations.

Disclaimer: This information is not personalized medical advice and should not replace consultation with a healthcare professional. Always consult a doctor or specialist for medical advice related to treatment options.

Daratumumab, a monoclonal antibody therapy, has been studied for various conditions, particularly multiple myeloma and kidney transplantation complications. Here is a summary of reported outcomes:

1. Multiple Myeloma:

   • A retrospective analysis in regional Australia focusing on relapsed or refractory multiple myeloma patients treated with daratumumab reported positive outcomes. Although specific data on response rates or survival benefits are not detailed, real-world evidence suggests efficacy in this patient group (PMID: 42542562).
   • Another study highlighted a high prevalence of iron deficiency among newly diagnosed multiple myeloma patients treated with daratumumab (PMID: 42543782). This indicates a potential need for monitoring and management of iron levels during treatment.
   • Clinical trial NCT03224507 (Phase 2) explored sequential therapy aimed at deep remission in multiple myeloma, although detailed outcomes were not provided.

2. Kidney Transplantation:

   • Evidence from serial protocol biopsies suggests daratumumab may have a treatment role in antibody-mediated kidney allograft rejection. Specific metrics of kidney function or histopathological improvements were not detailed, suggesting further research is needed to confirm efficacy (PMID: 42553987).

3. Other Conditions:

   • There is ongoing research into the use of daratumumab for AL amyloidosis and high-risk smoldering multiple myeloma, though results are still preliminary or not available (PMIDs: 42543634, 42535861).

Overall, the strength of evidence varies. While real-world analyses and some clinical trials suggest beneficial outcomes for multiple myeloma, detailed and consistent quantitative findings are limited, emphasizing the need for additional research.

Disclaimer: This summary is for informational purposes only and not a substitute for professional medical advice. Always consult a healthcare provider for treatment decisions.